echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > New developments in the "King Blast" portfolio Immune therapy changed from "small-population benefit" to "universal benefit"

    New developments in the "King Blast" portfolio Immune therapy changed from "small-population benefit" to "universal benefit"

    • Last Update: 2020-10-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, the rapid development of immunotherapy, cancer treatment has entered the "immune era."
    , however, PD-1/PD-L1 immunotherapy alone is not very effective, only about 20%.
    to further improve efficiency and shift immunotherapy from a 20 per cent "small group benefit" to a "benefit for all", scientists and clinicians began to use a combined approach.
    "CP" consisting of the "King Blast" combination (targeting the drug lenvatinib and the immunotherapy drug PD-1 inhibitor Keytruda) could benefit patients more in past studies.
    recently, the "King Blast" combination has sent another big message, its data on liver and stomach cancer published in the international authoritative journals, let's take stock of these new data.
    Liver cancer liver cancer for Chinese, is all doctors and patients of the "unstoppable pain": nearly half of the world's liver cancer patients are in China, so also known as "Chinese cancer";
    , for a long time, liver cancer is terminal, which means death.
    angiogenesic drugs, represented by lenforatini, and immunological drugs such as PD-1 antibodies, which are good news for patients with advanced liver cancer.
    keyNOTE-524 is an open, one-arm, multi-center study of the IB period.
    The combination of "King Blast" - lenphatinib and Keytruda two drugs for liver cancer treatment is of great significance, lenphatinib can regulate tumor-related macrophage changes, reverse the tumor immunosuppression microenviron environment, maintain immune activation, and Paboli bead monoantitor has the role of reactivation of T cells, so the combination of the two, can achieve better effect of killing tumors.
    early KEYNOTE-524 was explored only in patients with liver cancer in Japan, and to further clarify the safety and efficacy of other species, the group was then expanded to the United States.
    recently reported the clinical results of 100 patients using the "King Blast" combination of first-line therapy: 104 patients were included in the study group, of which 100 were included in the analysis.
    100 patients, mOS (medium total lifetime) was 22.0 months (95% CI: 20.4 months - not achieved), mPFS was 8.6 months (95% CI: 7.1-9.7 months, RECIST v1.1 per IIR), and disease control rate (DCR) was 88%.
    according to the mRECIST standard, the ORR is 46% (95% CI: 36.0%-56.3%), of which CR 11 cases, PR 35 cases, mitigation duration (DOR) is 8.6 months (95% CI:6.9 months - not reached).
    a real-world study by Professor Sun Huichuan of real-world research (Fudan University) on the real-world study of the joint PD-1 single-anti-first-line/second-line treatment of non-excisible/advanced primary liver cancer, a total of 59 patients with advanced liver cancer were included, and a total of 59 patients with advanced liver cancer were included. The da programme was used for first- and second-line treatment, with 60.5 per cent and 43.8 per cent ORR (mRECIST standards) achieved, respectively, of which 43 (72.9 per cent) patients treated the joint programme as first-line treatment and 6 (10.2 per cent) achieved R0 excision.
    For the "King Blast" combination, the expansion of the number of patients assessed has brought about an overall improvement in efficiency and survival, both created a history of liver cancer treatment, perhaps, we can say that this is our distance to overcome liver cancer, liver cancer "terminal" hat the closest moment.
    Gastric Cancer The Lancet-Oncology published the first- and second-stage clinical (EPOC1706) data for patients with advanced gastric cancer, with an objective remission rate of up to 69%, bringing new hope to gastric cancer patients.
    the study was an open one-arm Phase II clinical trial conducted at chiba National Cancer Research Center Hospital in Japan.
    patients in the group were: 20 years of age, metastatic or relapsed stomach adenocarcinoma or gastroesophageal junction tumor, ECOG score 0 or 1.
    patients were given oral 20 mg per day and Keytruda 200 mg every 3 weeks until the disease progressed, there was insatiable toxicity, or the patient withdrew from the trial.
    study endpoints are objective mitigation rates (ORRs) assessed based on RECIST.
    between 15 October 2018 and 25 March 2019, a total of 29 patients were recruited for first- or second-line treatment.
    the data cut-off, the mid-level follow-up time was 12.6 months (IQR 10.5-14.3).
    20 of the 29 patients (69%, 95% CI 49-85) achieved objective remission.
    progress-free lifetime (PFS) is 7.1 months (95% CI 5.4-13.7).
    20 patients survived and 9 died at the data cut-off.
    the medium total lifetime (OS) did not reach (95% CI 11.8 months - not arrived).
    kidney cancer as early as 2018, the FDA has awarded the "King Blast" combination in the field of kidney cancer breakthrough therapy recognition! In a recent data update, results from the Phase II partial renal cell carcinoma cohort in the KEYNOTE-146 study showed that patients in the group were given 200 mg of Keytruda intravenously every three weeks, while taking 20 mg of lenphedrine once a day orally.
    orR was 51% (95% CI: 41-61) in week 24 of this year; overall ORR was 55%, PR was 55%; mDOR was 12 months (95% CI: 9-18); mPFS was 11.7 months (95% CI: 9.) 4-17.7), 12-month PFS rate of 45% (95% CI: 32-57), mOS not yet reached (95% CI:16.7-NR), 12-month OS rate of 77% (95% CI: 67-85).
    from the above clinical trials, it can be seen that the combination of "Wang Fried" in liver cancer, stomach cancer and many cancerous fields, both a wide range of participation, as well as clinical verification and medical recognition of the therapeutic effect.
    The current mid- and late-stage cancer treatment has gradually entered the "targeting and immunity" of the era of joint treatment, I believe that in the near future, Lunvatini united Keytruda will continue to bring good news to Chinese patients, "Wang Blast" combination or will become the doctor's mind of the "ace"! Related reading: "K-drug combined with lenvatinist for 7 types of tumor efficacy data published" Source: 1. Sun, H.-C. (2020). Configuration therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study, ASCO Virtual Science Program, American Society of Clinical Oncology.2.A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). First Author: Andrew X. Zhu, Massachusetts General Hospital Cancer Center and Jiahui International Cancer Center, Boston, MA. ASCO 2020.3.Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial (published online forward of print, 2020 Jun 23. Lancet Oncol. 2020; S1470-2045 (20) 30271-0.4.747P - Aphase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocular carcinoma (uHCC): Updated.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.